CA
NZ
UK
AU
IND
US
• Fate Therapeutics (NASDAQ: FATE) has seen renewed market interest amid questions about improving cell-therapy sentiment.
• Foghorn Therapeutics (NASDAQ: FHTX) is attracting renewed attention as interest in precision medicine and gene-regulation drug development appears to broaden.
• Omeros (NASDAQ: OMER) has been drawing fresh market interest amid broader questions about whether sentiment toward biotech is improving.
• Minerva Neurosciences (NASDAQ: NERV) has attracted renewed market interest amid attention on neuroscience-focused biotech.
• Cue Biopharma (NASDAQ: CUE) is a clinical-stage immunotherapy company that has drawn renewed market attention amid heightened trading activity.
• Palisade Bio (NASDAQ: PALI) has attracted attention as interest in speculative small-cap biotech appears to stir.
• Greenwich LifeSciences (NASDAQ: GLSI) has drawn renewed market interest amid attention on cancer-vaccine research.
• Rafael Holdings (NYSE: RFL) is a US holding company with interests spanning clinical-stage biotechnology assets and real estate.
• SELLAS Life Sciences (NASDAQ: SLS) has attracted renewed market interest amid broader attention on oncology biotech.
• $50 Million in Upfront Proceeds: Pyxis Oncology secured immediate gross proceeds through a newly announced private placement financing.
Please wait processing your request...